Chemotherapy-induced cardiotoxicity

Current Heart Failure Reports

Volumn 9, Issue 2, 2012, Pages 117-127

  Shaikh, Amir Y ^a   Shih, Jeffrey A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Anthracycline; Cardio oncology; Cardiomyopathy; Cardiotoxicity; Chemotherapy; Doxorubicin; Heart failure; Management; TKIs; Trastuzumab; Tyrosine kinase inhibitors

Indexed keywords

ACETYLCYSTEINE; ANTHRACYCLINE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARNITINE; CARVEDILOL; CLOFARABINE; CYCLOPHOSPHAMIDE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMATINIB; LAPATINIB; MITOXANTRONE; RAZOXANE; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VALSARTAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DOPPLER ECHOGRAPHY; DRUG EFFICACY; EARLY DIAGNOSIS; GASTROINTESTINAL STROMAL TUMOR; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HEPATOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MORBIDITY; MULTIPLE MYELOMA; NEPHROBLASTOMA; OVARY CANCER; OVERALL SURVIVAL; PROSTATE CANCER; RISK FACTOR; SARCOMA; CHEMICALLY INDUCED DISORDER; HEALTH SURVEY; METHODOLOGY; PRACTICE GUIDELINE; REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; HEART FAILURE; HUMANS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 84864875947     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0083-y     Document Type: Article

References (65)

1. Geiger S, Lange V, Suhl P, et al. Anticancer therapy induced cardiotoxicity: review of the literature. Anti Canc Drug. 2010;21 (6):578-90.
2. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010 Jun 29;10:337. This is a thorough review of the literature. Due to the small trials, meta-analyses are essential with regards to this topic.
3. Zuppinger C, Suter TM. Cancer therapy-associated cardiotoxicity and signaling in the myocardium. J Cardiovasc Pharmacol. 2010;56 (2):141-6.
4. van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006.
5. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005006. This is an effective Cochrane review on preventing or reducing cardiotoxicity from anthracyclines.
6. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in survivors of childhood cancer. NEJM. 2006;355(15):1572-82. (Pubitemid 44547808)
7. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47. This is an excellent review on the topic.
8. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
9. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105-13.
10. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-6.
11. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20 (5):1215-21. (Pubitemid 34177427)
12. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23 (31):7820-6. (Pubitemid 46657379)
13. Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53 (2):114-20.
14. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122-31.
15. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002;4(3):235-42. (Pubitemid 35190345)
16. Quezado ZM,WilsonWH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31-6. (Pubitemid 23007969)
17. Martin M, Pienkowski T, Mackey J, Breast Cancer International Research Group 001 Investigators, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13. (Pubitemid 40740554)
18. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9 (4):320-8. (Pubitemid 47377031)
19. Pande A, Lombardo J, Spangenthal E, et al. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.Anticancer Res. 2007;27(5B):3465-70. (Pubitemid 47607487)
20. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117-23.
21. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356 (2):115-24. (Pubitemid 46089672)
22. Palumbo A, Rajkumar SV, Dimopoulos MA, International Myeloma Working Group, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2):414-23. (Pubitemid 351255436)
23. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609-15. (Pubitemid 46594053)
24. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Canc Inst. 2010;102(1):14-25.
25. Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996; 53:461-70. (Pubitemid 26388387)
26. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118 (1):92-8. (Pubitemid 19183582)
27. Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994;33 (6):645-9. (Pubitemid 24345370)
28. Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68(2):435-8.
29. Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992;19(2):394-401.
30. Sawaya H, Sebag IA, Plana JC, et al. Early detection and predictor of cardiotoxicity in chemotherapy- treated patients. Am J Cardiol. 2011;107:1375-80. This is a recent article reviewing the risk factors, surveillance, and means of identifying cardiotoxicity.
31. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517-22.
32. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-54. (Pubitemid 38737923)
33. Cardinale D, Salvatici M, Sandri MT. Review: role of biomarkers in cardioncology. Clin Chem Lab Med. 2011 Sep 6.
34. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405-10. (Pubitemid 41060872)
35. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-14.
36. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900-5. (Pubitemid 28446849)
37. Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risk analysis of 1097 breast cancer patients. J Natl Canc Inst. 2008;100:1058.
38. Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Investig New Drugs. 1985;3:123.
39. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005-24. (Pubitemid 40667518)
40. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117-27.
41. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318-32. (Pubitemid 27167363)
42. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 1996;14:3112-20. (Pubitemid 26408804)
43. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362-72. (Pubitemid 26050996)
44. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of highdose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998;16:86-92. (Pubitemid 28041583)
45. Marty M, Espie M, Llombart A, Dexrazoxane Study G, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17:614-22.
46. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008:CD003917. This is a typical Cochrane review on cardioprotective strategies with anthracyclines.
47. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258-62. (Pubitemid 44855419)
48. Waldner R, Laschan C, Lohninger A, et al. Effects of doxorubicincontaining chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol. 2006;132:121-8.
49. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by Nacetylcysteine. Semin Oncol. 1983;10:53-5. (Pubitemid 13092606)
50. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492.
51. al-Shabanah O,MansourM, el-Kashef H, et al. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int. 1998;45:419-27. (Pubitemid 28331955)
52. Sacco G, Bigioni M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001;414:71-8. (Pubitemid 32174877)
53. VaynblatM, Shah HR, Bhaskaran D, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583-6. (Pubitemid 35278509)
54. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20. This is a rare prospective study assessing treatment with standard heart failure medications. Unfortunately, there was no comparative placebo arm.
55. Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56:1644.
56. Fazio S, Calmieri EA, Ferravate B, et al. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 1998;21:777-9. (Pubitemid 28464881)
57. Noori A, Lindenfeld J, Wolfel E, et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000;6:115-9.
58. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13:699-709. (Pubitemid 34567375)
59. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicintreated survivors of childhood cancer. J Clin Oncol. 2002;20:517-22.
60. Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicininduced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:201-19.
61. Musci M, Loebe M, Grauhan O, et al. Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents. Transplant Proc. 1997;29(1-2):578-9. (Pubitemid 27123535)
62. Dorent R, Pavie A, Nataf P, et al. Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy. Transplant Proc. 1995;27(2):1683.
63. Christiansen S. Clinical management of doxorubicin-induced heart failure. J Cardiovasc Surg. 2011;52:13-7.
64. Harris L, Batist G, Belt R, TLC D-99 Study Group, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as firstline therapy of metastatic breast carcinoma. Cancer. 2002;94 (1):25-36. (Pubitemid 34049039)
65. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19 (5):1444-54. (Pubitemid 32202552)